The use of statins in optimising reduction of cardiovascular risk: focus on fluvastatin |
| |
Authors: | Corsini A |
| |
Affiliation: | Department of Pharmacological Sciences, University of Milan, Milan, Italy. alberto.corsini@unimi.it |
| |
Abstract: | Patients with widely differing degrees of cardiovascular risk can derive benefit from effective lipid-lowering therapy with statins, including patients with normal or low cholesterol levels. Clinical trials with fluvastatin have shown that it is effective in patients across a broad spectrum of cardiovascular risk. The lipid-lowering effects of fluvastatin are smaller than some statins, but major clinical outcome studies have consistently demonstrated morbidity and mortality benefits with reductions of low-density lipoprotein cholesterol of <30%. As treatment with statins is generally life-long and patients often receive multiple concomitant medications, optimal statin therapy should be well tolerated and serious consideration should be given to the avoidance of drug interactions. Although serious side-effects of statins are very rare, it is important that fluvastatin is less susceptible to drug interactions than other statins, because serious side-effects of statin therapy are generally associated with concomitant medications affecting statin metabolism. In addition, an extended-release formulation of fluvastatin has been developed to provide liver selectivity with a sustained exposure to the drug, thus improving its efficacy, and safety and tolerability profiles. |
| |
Keywords: | HMG‐CoA reductase inhibitors hypercholesterolaemia adverse effects drug interactions cardiovascular benefits pleiotropic effects |
本文献已被 PubMed 等数据库收录! |
|